IP Library › Granted Patent US 11,975,114
Granted Patent B2
US 11,975,114 · App. 17/168,128 · Granted May 7, 2024

Single use, topical, hydrophilic article with a hemostatic foam

Inventor: David Lang (Venore, TN)
A61L15/425A61F13/0226A61F13/0259A61L15/24A61L15/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,975,114
App. No.
17/168,128
Granted
May 7, 2024
Kind
B2
Abstract

A hemostatic surface application device having a region of hemostatic foam for contact with a patient's skin where a wound exists or is created, the device includes: a release layer, the release layer in contact with a hemostatic flexible foam section, and a structural foam layer having a front side and a back side surrounding the hemostatic flexible foam layer, forming a generally central hemostatic surface exposed through the front side of the surrounding structural foam layer, and a support layer adhered to the backside of the structural foam layer.

Claims (9)

1. A method of reducing excessive blood flow off an exterior surface wound of a patient comprising:

a) removing the release layer of a hemostatic surface application device comprising a hemostatic surface application device having a region of hemostatic foam for contact with a patient's skin where a wound exists or is created, the device comprising: a release layer, the release layer in contact with a hemostatic flexible foam layer, and a structural foam layer having a front side and a back side surrounding the hemostatic flexible foam layer, forming a generally central hemostatic surface exposed through the front side of the surrounding structural foam layer, and a support layer adhered to the back side of the structural foam layer; and

b) applying the generally central hemostatic surface to a limited area of skin of the patient; and

c) wherein after applying the generally central hemostatic surface to a limited area of skin of the patient, a catheter or needle is inserted through the hemostatic foam layer of the hemostatic surface application device and into the skin of the patient.

2. The method of claim 1 wherein after inserting the catheter or needle through the skin of the patient, blood exudes from the skin of the patient and is clotted by the hemostatic foam layer.

3. The method of claim 2 wherein the hemostatic flexible foam layer retains at least 99.5% of total weight of the hemostatic flexible foam layer when in contact with blood exuding from the skin of the patient for 1 minute.

4. The method of claim 3 wherein the hemostatic flexible foam layer comprises a polysaccharide foam composition.

5. The method of claim 4 wherein the hemostatic flexible foam layer has a thickness at least 1% greater than the thickness of the structural foam layer.

6. The method of claim 4 wherein the structural foam layer is a polyurethane foam.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2021
From: LANG, DAVID
To: KOAG LLC
Reel/Frame 055168/0463 →
Continuity (1)
Related Publication 20220241454A1 · Aug 4, 2022
Cited By (1)
US 12,311,063